Probability of Antibody Formation against Circumsporozoite Protein of Plasmodium vivax among Korean Malaria Patients.
- Author:
Ho Woo NAM
1
;
Kyoung Ju SONG
;
Hye Jin AHN
;
Zhaoshou YANG
;
Chom Kyu CHONG
;
Pyo Yun CHO
;
Seong Kyu AHN
;
Tong Soo KIM
Author Information
1. Department of Parasitology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Plasmodium vivax;
central repeating domain;
circumsporozoite protein;
variant VK210;
rapid diagnostic test
- MeSH:
Amino Acid Sequence;
Antibodies, Protozoan/*blood/immunology;
Antibody Formation;
Antigens, Protozoan/immunology;
Base Sequence;
Humans;
India;
Malaria, Vivax/*diagnosis/*epidemiology/immunology;
Merozoite Surface Protein 1/genetics/*immunology;
Plasmodium vivax/genetics/immunology;
Protozoan Proteins/genetics/*immunology;
Reagent Kits, Diagnostic;
Recombinant Proteins/diagnostic use/immunology;
Republic of Korea/epidemiology;
Sequence Analysis, DNA;
Seroepidemiologic Studies;
Uganda
- From:The Korean Journal of Parasitology
2014;52(2):143-149
- CountryRepublic of Korea
- Language:English
-
Abstract:
To evaluate the seroprevalence against circumsporozoite protein (CSP) of Plasmodium vivax in sera of Korean patients, the central repeating domain (CRD) of CSP was cloned and analyzed. From the genomic DNA of patient's blood, 2 kinds of CSPs were identified to belong to a VK210 type, which is the dominant repeating of GDRA(D/A)GQPA, and named as PvCSPA and PvCSPB. Recombinantly expressed his-tagged PvCSPA or PvCSPB in Escherichia coli reacted well against sera of patients in western blot, with the detecting rate of 47.9% (58/121), which included 15 cases positive for PvCSPA, 6 cases positive for PvCSPB, and 37 cases for both. The mixture of PvCSPA and PvCSPB was loaded to a rapid diagnostic test kit (RDT) and applied with the same set of patient sera, which resulted in detection rates of 57.0% (69/121). When the protein sequences of PvCSPA were compared with those of P. vivax in endemic regions of India and Uganda, they were compatibly homologous to PvCSPA with minor mutations. These results suggested that the recombinant PvCSPA and PvCSPB loaded RDT may be a milestone in latent diagnosis which has been a hot issue of domestic malaria and important for radical therapy in overlapped infections with P. falciparum in tropical and subtropical areas. During the biological process of malarial infection, exposure of CSP to antigen-antibody reaction up to 57.0% is the first report in Korea.
